consider mycobacterial infections and inquire about recent pedicures in patients with apparent lower-extremity furunculosis. Tissue cultures and sensitivity studies should be performed to guide treatment, given the widespread antibiotic resistance of mycobacteria species. Early recognition of the organisms and institution of appropriate therapy are critical. Physicians and the public need to be educated about the possibility of infections following pedicures, and physicians should inquire about pedicures when faced with nonhealing furunculosis of the lower legs. Public health measures should be explored to protect against such infections given the recent increase in popularity of the nail care industry.

REFERENCES

Topical photodynamic therapy for primary cutaneous B-cell lymphoma: A pilot study

Moira Mori, MD, Piero Campolmi, MD, Luciano Mavilia, MD, Riccardo Rossi, MD, Pietro Cappugi, MD, and Nicola Pimpinelli, MD

Florence, Italy

Photodynamic therapy (PDT) is a treatment based on the accumulation of a photosensitizer in the target cells and their selective destruction by irradiation with visible light. In the past 10 years, several patients with cutaneous T-cell lymphoma have been successfully treated. The use of PDT in cutaneous B-cell lymphoma has not been reported to date. We report the successful PDT treatment of 3 patients with early primary cutaneous B-cell lymphoma. (J Am Acad Dermatol 2006;54:524-6.)

I ndolent primary cutaneous B-cell lymphomas (CBCL), that is, follicular center and marginal zone lymphoma according to the European Organization for Research and Treatment of Cancer (EORTC) and the recent consensus World Health Organization–EORTC classification, are characterized by mostly local or regional extension and very good prognosis (rare extracutaneous spread, despite relatively frequent cutaneous relapses, and 5-year survival rate >95%). Both types are highly responsive to local radiotherapy (RT). Small, isolated
lesions can be surgically excised, with or without additional RT.2 The treatment with multiple-agent chemotherapy should be restricted, at presentation, to the definitely occasional patients with disseminated lesions, to those refractory to or with multiple relapses after RT.2 Other treatment modalities, such as intralesional cisplatin-epinephrine gel3 and anti-CD20 monoclonal antibody,2 has been reported as being of possible help in specific circumstances.

Photodynamic therapy (PDT) is a treatment modality based on the administration of a photosensitizing compound that accumulates in the target cells, followed by selective irradiation of the lesion with visible light. The combination of two individually nontoxic elements, drug and light, is responsible for PDT-mediated response (reviewed in Kalka, Merk, and Mukhtar4), presumably via apoptotic cell death as a major mechanism5 with minimal or no necrotic changes. The most widely used photosensitizer is aminolevulinic acid (ALA), first proposed in 1978 by Dougherty et al6 for the treatment of mycosis fungoides (MF). To date, other case series of MF patients (both in plaque and tumor stages) and 2 patients with CD30+ cutaneous T-cell lymphoma (CTCL) successfully treated with PDT have been reported.7-15

To date, no reports are available concerning the use of systemic or local PDT in the treatment of CBCL. We report herein about the successful ALA-PDT treatment of 3 patients with early CBCL.

**PATIENTS AND METHODS**

Three patients with CBCL, whose data are summarized in Table 1, were treated with PDT. The diagnosis was established by routine histopathology and immunophenotyping according to the WHO-EORTC classification. In two patients (1 and 2; Table I), skin lesions (thin plaques) had never been treated. In patient 3, the treated lesion had relapsed 6 months after complete remission obtained by orthovolt RT.

ALA 20% (oil-in-water emulsion) was applied topically to the lesion and to adjacent skin under an occlusive and light-shielding dressing for 4 hours in patients 1 and 3. In patient 2, the methyl ester of ALA (Metvix; Photocure, Oslo, Norway and Galderma, Paris, France) was applied. The red fluorescence of porphyrins was visualized with Wood’s light before treatment. Fluorescence was seen in all cases. The ALA-treated areas were then exposed to incoherent light using a light-emitting diode lamp (Aktilite PDT, model CL128; Photocure ASA, Oslo, Norway) at a wavelength of 630 nm and a light dose of 37 J/cm² with light intensity of 70 to 100 mW/cm². It illuminates areas from 80 to 180 mm at a distance from 50 to 80 mm. The patients were examined after 1 week, and, depending on the clinical results, the treatment was repeated (patient 3). Four-millimeter punch biopsy specimens were taken before treatment and after clinical remission. Clinical evaluation was performed monthly after PDT, with an 8- to 24-month follow-up.

**RESULTS**

The treatment was well tolerated by all patients without local anesthetics. The results are summarized in Table 1. All patients underwent complete remission, defined as clinical and histologic complete remission, with a maximum of two treatment sessions at 1-week intervals. Two patients (1 and 2) were in complete remission after 1 week from the first (and only) PDT session. Patient 3 underwent complete remission after 1 week from the second PDT session (Fig 1).

**DISCUSSION**

PDT consists of the application of a photosensitizing agent and irradiation with noncoherent light
Photoactivation of photosensitizing porphyrins, which selectively accumulate in tumor cells, induces healing with minimal or no necrotic changes. PDT has been successfully used in CTCL (MF and CD30\(^+\) CTCL).\(^7\)-\(^12\)

We treated 3 patients with early CBCL, with complete remission achieved in all 3 after a maximum of two PDT sessions. The successful use of ALA-PDT in indolent CBCL, to our knowledge reported herein for the first time, suggests a possible role of PDT in the treatment of localized, thin plaques as an alternative to local RT, which has to be considered the treatment of choice. Additional studies on larger series will hopefully contribute to clarify this issue.

**Table I. Summary of results in 3 patients with indolent primary cutaneous B-cell lymphoma**

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Age (y)/sex</th>
<th>Disease/stage</th>
<th>Previous tx</th>
<th>PDT sessions</th>
<th>Photosensitizer</th>
<th>Results</th>
<th>Follow-up (mo)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>62/F</td>
<td>CBCL (FCL)</td>
<td>None</td>
<td>1</td>
<td>ALA</td>
<td>CR</td>
<td>17</td>
</tr>
<tr>
<td>2</td>
<td>38/F</td>
<td>CBCL (MZL)</td>
<td>None</td>
<td>1</td>
<td>Metvix</td>
<td>CR</td>
<td>8</td>
</tr>
<tr>
<td>3</td>
<td>56/M</td>
<td>CBCL (MZL)</td>
<td>RT</td>
<td>2</td>
<td>ALA</td>
<td>CR</td>
<td>24</td>
</tr>
</tbody>
</table>

ALA, Aminolevulinic acid 20%, oil-in-water emulsion; CBCL, cutaneous B-cell lymphoma; CR, complete response; FCL, follicle center lymphoma; Metvix, methyl ester of ALA; MZL, marginal zone lymphoma; PDT, photodynamic therapy; RT, orthovolt radiotherapy (20 Gy); tx, therapy.

REFERENCES